Articles On Starpharma Holdings (ASX:SPL)

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to extend its winning streak. At the time of writing, the benchmark index is up 0.4% to 5,986.9 points. Four shares that have failed to follow the market higher today...

The federal government is set to announce a $1.5 billion plan and list six key sectors that will shape Australia’s manufacturing future. The Australia Financial Review listed that the six priority areas that will receive the most governmen...

It has not been a positive day so far for investors, with the ASX market down following Wall Street’s losses overnight. The All Ordinaries Index (ASX: XAO) has dropped 1.3% to 6,059 points. The Starpharma Holdings Limited (ASX: SPL) share...

The S&P/ASX 200 Index (ASX: XJO) has come under pressure on Wednesday and is on course to record a sizeable decline. The benchmark index is down 1.15% to 5,883.1 points in late morning trade. Four shares that have fallen more than most...

Listed pharmaceutical company Starphrama (ASX: SPL) has today completed a $45 million oversubscribed institutional placement to fast track the launch of its COVID-19 nasal spray. The spray, called SPL7013, has been shown to inactivate mor...

The market may be pushing higher this afternoon but missing out on the action are the shares of Corporate Travel Management Ltd (ASX: CTD) and Starpharma Holdings Limited (ASX: SPL). Both companies requested trading halts this morning befo...

The Rhinomed Ltd (ASX: RNO) share price surged to a six-month high as it takes a leaf out of the Starpharma Holdings Limited (ASX: SPL) playbook. The Rhinomed share price rallied 84% ahead of the market close to $0.14 after management said...

Starpharma (ASX:SPL) has halted the laboratory testing of its antiviral SPL7013 against COVID-19 after confirmation it is more than 99.9 per cent effective against the virus.

The Starpharma Holdings Limited (ASX: SPL) share price has been among the best performers on Monday. In afternoon trade the dendrimer products developer’s shares are up 8% to $1.73. Why is the Starpharma share price zooming higher? Investo...

Testing of Starpharma's (ASX: SPL) nasal spray has shown the drug is virucidal, meaning it can inactivate more than 99.9 per cent of SARS-CoV-2, the virus that causes COVID-19. As such, production of the spray, which can inactivate the vi...

Testing of Starpharma's (ASX: SPL) nasal spray has been shown to inactivate more than 99.9 per cent of SARS-CoV-2, the virus that causes COVID-19. The effectiveness of the treatment depends on its use before or after exposure to the virus...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing the benchmark index is up 0.5% to 5,890.5 points. Four shares that have climbed more than most today are li...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

Summary ASX 300 listed healthcare player Starpharma Holdings Limited receives A$1 million funding from MRFF for its SPL7013 COVID-19 nasal spray. The Company intends to utilise the funds to accelerate the development and commercialisati...

Shares in Starpharma (ASX: SPL) are on the rise after the pharmaceutical company announced it has received $1 million in funding to develop its COVID-19 nasal spray. The company was selected by the Australian Government's Medical Research...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record another strong gain. At the time of writing the benchmark index is up 1% to 6,121.7 points. Four shares that are climbing more than most today are listed below....

The Starpharma Holdings Limited (ASX: SPL) share price was up 5.52% at the time of writing to $1.72. This came after the company announced a funding award to develop a COVID-19 nasal spray.  What was in the announcement? Starphama said it...

03 Sep 2020 - Starpharma (ASX:SPL) has been awarded $1 million in matched funding by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (…

The market reacted positively to the Starpharma Holdings Ltd [ASX:SPL] announcement and pushed the share price up to trade at $1.70 yesterday. The SPL share price is retracing now, down 7.35%, trading at $1.57... The post Starpharma Share P...

Summary ASX 300 healthcare company Starpharma Holdings has applied its novel DEP® drug delivery technology to develop a long-acting, water-soluble formulation of remdesivir. Starpharma’s DEP® remdesivir is a water-soluble nanopart...

Pharmaceuticals developer Starpharma (ASX: SPL) has been riding positive investor sentiment for just over a week now after the announcements of two major COVID-19 breakthroughs. Last week, SPL shares rose by about 40 per cent in response...

01 Sep 2020 - Starpharma (ASX:SPL) today announced it has applied its novel DEP® drug delivery technology to create a long-acting, water soluble version of remdesivir.

In afternoon trade the the S&P/ASX 200 Index (ASX: XJO) is off its lows but still deep in the red. At the time of writing the benchmark index is down 1.9% to 5,943 points. Four shares that have not let that hold them back are listed be...

The Starpharma Holdings Limited (ASX: SPL) share price has been a positive performer on Tuesday. In morning trade the dendrimer products developer’s shares have jumped 12% to a record high of $1.70. Why is the Starpharma share price stormi...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

The Starpharma Holdings Limited (ASX: SPL) share price has been on fire on Thursday following its full year results release. The dendrimer products developer’s shares jumped to a 52-week high of $1.51 at one stage. How did Starpharma perfo...

27 Aug 2020 - Starpharma (ASX:SPL) report their revenue is up 142 per cent to $6.56 million.

A quick wrap of the ASX’s key winners and losers on Tuesday, August 25. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 782 stocks rose, 682 declined and...

The Starpharma Holdings Limited (ASX: SPL) share price bolted more than 14% in early trade today. The positive price action follows an announcement from the company regarding a nasal spray for COVID-19. Details on Starpharma’s nasal spray...

Starpharma (ASX:SPL) has updated on progress in the development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013....

Australian company Starpharma (ASX:SPL) has signed a new research partnership with Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical to develop several DEP nanoparticle formulations for an anti-infective drug.

The Starpharma Holdings Limited (ASX: SPL) share price is bucking the market downtrend today after the biotech announced a new partnership deal. The news isn’t quite as exciting as Mesoblast limited’s (ASX: MSB) FDA announcement, but share...

The S&P/ASX 200 Index (ASX: XJO) has started the week on a disappointing note. In late morning trade the benchmark index is down 0.9% to 6,070.1 points. Four shares that have not let that hold them back are listed below. Here’s why the...

With its stock plumbing all time lows, G Medical (ASX:GMV) is making good on a promise first made in 2018 to list on the NASDAQ tech exchange in New York. The medical device company will delist from the ASX in order to list in the US, an ev...

Starpharma (ASX:SPL) has announced the opening of the MD Anderson Cancer Center as another site for the phase one trial of AZD0466 - AstraZeneca’s first DEP product.

After a strong start to the day, the S&P/ASX 200 Index (ASX: XJO) is currently fighting hard to stay in positive territory. In late morning trade the benchmark index is up slightly to 5,944.4 points. Four shares that are climbing more...

16 Jun 2020 - Starpharma (ASX:SPL) today announced that VivaGel BV has been launched in Central and Eastern European region.

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

The S&P/ASX 200 Index (ASX: XJO) is out of form and on course to record a disappointing decline. In late morning trade the benchmark index is down 1.45% to 5,387.6 points. Four shares that have not let that hold them back today are lis...

The S&P/ASX 200 Index (ASX: XJO) may be sinking lower today, but that hasn’t stopped the Starpharma Holdings Limited (ASX: SPL) share price from rocketing higher. In morning trade the dendrimer products developer’s shares zoomed a mass...

04 Mar 2020 - Starpharma (ASX:SPL) today announced that following the successful launch of the VivaGel antiviral condom by Okamoto Industries in Japan, they are now seeking to expa…

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher this morning following the release of an update on its VivaGel product. At the time of writing its shares have avoided the market selloff and are up 0.5% to $1.01. Wh...

The Starpharma Holdings Limited (ASX: SPL) share price has dropped lower with the market on Monday following the release of its half year results. At the time of writing the dendrimer products developer’s shares are down 6.5% to $1.14. How...

Sleep apnoea — or sleep suffocation as some have taken to calling it — is big business on the ASX, spanning billion-dollar ResMed (ASX:RMD) to a group of small caps. Oventus (ASX:OVN), one of those small caps, is the latest this month to ad...

AstraZeneca has paid a $4.5 million milestone payment to Australian company Starpharma (ASX:SPL) following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466.

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Thursday after the release of a positive update. In morning trade the dendrimer products developer’s shares are up 3% to $1.17. What did Starpharma announce? Inves...

Starpharma Holdings (SPL) has received a milestone $4.5 million payment from biopharmaceutical giant AstraZeneca The grant follows the first successful human dosing in AstraZeneca’s cancer treatment trial, which uses Starpharma’s drug deli...

The Starpharma Holdings Limited (ASX: SPL) share price will be on watch today following an update on its phase 1 trial of AZD0466. At the time of writing, the Starpharma share price is up by 2.16%. What does Starpharma do? Starpharma is an...

Two more coronavirus infections were released to the ASX in the last 24 hours, but while one was bad, it turns out the other wasn’t part of the epidemic at all. Uscom (ASX:UCM) says sales of its haemodynamic monitoring device in China, whic...